Validation of a Computerized test of Functional Capacity

Schizophrenia Research

Volumn 175, Issue 1-3, 2016, Pages 90-96

  Keefe, Richard S E ^a,b   Davis, Vicki G ^b   Atkins, Alexandra S ^b   Vaughan, Adam ^b   Patterson, Tom ^c   Narasimhan, Meera ^d   Harvey, Philip D ^e,f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NeuroCog Trials Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cognition; Computerized testing; Everyday functioning; Functional capacity; Virtual reality

Indexed keywords

ADULT; ARTICLE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DSM-IV-TR; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOMETRY; RELIABILITY; SCHIZOPHRENIA; SCORING SYSTEM; SENSITIVITY ANALYSIS; SKILL; TEST RETEST RELIABILITY; VALIDATION PROCESS; VALIDITY; VIRTUAL REALITY; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER INTERFACE; FOLLOW UP; MULTICENTER STUDY; PSYCHOLOGIC TEST; PSYCHOLOGICAL INTERVIEW; PSYCHOLOGICAL RATING SCALE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; DIAGNOSIS, COMPUTER-ASSISTED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGICAL TESTS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; USER-COMPUTER INTERFACE;

EID: 84963681253     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.03.038     Document Type: Article

References (41)

1. Atkins, A.S., Stroescu, I., Spagnola, N.B., Davis, V.G., Patterson, T.D., Narasimhan, M., Harvey, P.D., Keefe, R.S., Assessment of age-related differences in functional capacity using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). J. Prev. Alzheimers Dis. 2 (2015), 121–127.
2. Bilder, R.M., Goldman, R.S., Robinson, D., Reiter, G., Bell, L., Bates, J.A., Pappadopulos, E., Willson, D.F., Alvir, J.M., Woerner, M.G., Geisler, S., Kane, J.M., Lieberman, J.A., Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 157 (2000), 549–559.
3. Bowie, C.R., Harvey, P.D., Cognition in schizophrenia: impairment, determinants, and. functional importance. Psychiatr. Clin. N. Am. 28 (2005), 613–633.
4. Bowie, C.R., McGurk, S.R., Mausbach, B., Patterson, T.L., Harvey, P.D., Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior. Am. J. Psychiatry 169 (2012), 710–718.
5. Buchanan, R.W., Davis, M., Goff, D., Green, M.F., Keefe, R.S.E., Leon, A., Nuechterlein, K., Laughren, T., Levin, R., Stover, E., Fenton, W., Marder, S., A summary of the FDA-NIMH-MATRICS workshop on clinical trial designs for neurocognitive drugs for schizophrenia. Schizophr. Bull. 31 (2005), 5–19.
6. Buchanan, R.W., Keefe, R.S.E., Umbricht, D., Green, M.F., Laughren, T., Marder, S.R., The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?. Schizophr. Bull. 37 (2011), 1209–1217.
7. Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W.W., Keefe, R.S., Boter, H., Keet, I.P., Prelipceanu, D., Rybakowski, J.K., Libiger, J., Hummer, M., Dollfus, S., Lopez-Ibor, J.J., Hranov, L.G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rossler, A., Kahn, R.S., Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 166 (2009), 675–682.
8. Durand, D., Strassnig, M., Sabbag, S., Gould, F., Twamley, E.W., Patterson, T.L., Harvey, P.D., Factors influencing self-assessment of cognition and functioning in schizophrenia: implications for treatment studies. Eur. Neuropsychopharmacol. 25 (2015), 185–191.
9. Fisher, M., Holland, C., Merzenich, M.M., Vinogradov, S., Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am. J. Psychiatry 166 (2009), 805–811.
10. Goldberg, T.E., Keefe, R.S., Goldman, R.S., Robinson, D.G., Harvey, P.D., Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 35 (2010), 1053–1062.
11. Green, M.F., Nuechterlein, K.H., Kern, R.S., Baade, L.E., Fenton, W.S., Gold, J.M., Keefe, R.S.E., Mesholam-Gately, R., Seidman, L.J., Stover, E., Marder, S.R., Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS psychometric and standardization study. Am. J. Psychiatry 165 (2008), 221–228.
12. Green, M.F., Schooler, N.R., Kern, R.S., Frese, F.J., Granberry, W., Harvey, P.D., Karson, C.N., Peters, N., Stewart, M., Seidman, L.J., Sonnenberg, J., Stone, W.S., Walling, D., Stover, E., Marder, S.R., Evaluation of functionally-meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am. J. Psychiatry 168 (2011), 400–407.
13. Harvey, P.D., Silverman, J.M., Mohs, R.C., Parrella, M., White, L., Powchik, P., Davidson, M., Davis, K.L., Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol. Psychiatry 45 (1999), 32–40.
14. Harvey, P.D., Keefe, R.S.E., Patterson, T.L., Heaton, R.K., Bowie, C.R., Abbreviated neuropsychological assessments in schizophrenia: association with different outcomes measures. J. Clin. Neuropsychol. 31 (2009), 462–471.
15. Jaeger, J., Berns, S., Uzelac, S., Davis-Conway, S., Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 145 (2006), 39–48.
16. Javitt, D.C., Buchanan, R.W., Keefe, R.S.E., Kern, R., McMahon, R.P., Green, M.F., Lieberman, J., Goff, D.C., Csernansky, J.G., McEvoy, J.P., Jarskog, F., Seidman, L.J., Gold, J.M., Kimhy, D., Nolan, K.S., Barch, D.S., Ball, M.P., Robinson, J., Marder, S.R., Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr. Res. 136 (2012), 25–31.
17. Kay, S.R., Fiszbein, A., Opler, L.A., The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987), 261–276.
18. Keefe, R.S.E., Poe, M., Walker, T.M., Kang, J.W., Harvey, P.D., The Schizophrenia Cognition Rating Scale (SCoRS): an interview-based assessment and its relationship to cognition, real-world functioning and functional capacity. Am. J. Psychiatry 163 (2006), 426–432.
19. Keefe, R.S.E., Bilder, R.M., Harvey, P.D., Davis, S.M., Palmer, B.W., Gold, J.M., Meltzer, H.Y., Green, M.F., Miller, D.D., Canive, J.M., Adler, L.W., Manschreck, T.C., Swartz, M., Rosenheck, R., Perkins, D.O., Walker, T.M., Stroup, T.S., McEvoy, J.P., Lieberman, J.A., Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31 (2006), 2033–2046.
20. Keefe, R.S.E., Bilder, R.M., Davis, S.M., Harvey, P.D., Palmer, B.W., Gold, J.M., Meltzer, H.Y., Green, M.F., Capuano, G., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Davis, C.E., Hsiao, J.K., Lieberman, J.A., CATIE Investigators, Neurocognitive Working Group: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia. Arch. Gen. Psychiatry 64 (2007), 633–647.
21. Keefe, R.S.E., Malhotra, A.K., Meltzer, H., Kane, J.M., Buchanan, R.W., Murthy, A., Sovel, M., Li, C., Goldman, R., Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33 (2008), 1217–1228.
22. Keefe, R.S.E., Davis, V.G., Spagnola, N.B., Hilt, D., Dgetluck, N., Ruse, S., Patterson, T.D., Narasimhan, M., Harvey, P.D., Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. Eur. Neuropsychopharmacol. 25 (2015), 176–184.
23. Keefe, R.S., Meltzer, H.A., Dgetluck, N., Gawryl, M., Koenig, G., Moebius, H.J., Lombardo, I., Hilt, D.C., Randomized, double-blind, placebo-controlled study of encenicline, an α-7 nicotinic acetylcholine receptor agonist as an adjunctive treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 40 (2015), 3053–3060.
24. Kern, R.S., Nuechterlein, K.H., Green, M.F., Baade, L.E., Fenton, W.S., Gold, J.M., Keefe, R.S.E., Mesholam-Gately, R., Mintz, J., Seidman, L.J., Stover, E., Marder, S.R., The MATRICS Consensus Cognitive Battery; part 2: co-norming and standardization. Am. J. Psychiatry 165 (2008), 214–220.
25. Laughren, T., A regulatory perspective on psychiatric syndromes in Alzheimer's disease. Am. J. Geriatr. Psychiatry 9:9 (2001), 340–345.
26. Leifker, F.R., Bowie, C.R., Harvey, P.D., The determinants of everyday outcomes in schizophrenia: influences of cognitive impairment, clinical symptoms, and functional capacity. Schizophr. Res. 115 (2009), 82–87.
27. Leifker, F.R., Patterson, T.L., Heaton, R.K., Harvey, P.D., Validating measures of real-world outcome: the results of the VALERO Expert Survey and RAND Appropriateness Panel. Schizophr. Bull. 37 (2011), 334–343.
28. Mahableshwarkar, A.R., Zajecka, J., Jacobson, W., Chen, Y., Keefe, R.S., A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 40 (2015), 2025–2037.
29. Marder, S.R., Fenton, W., Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr. Res. 72 (2004), 5–9.
30. McClure, M.M., Bowie, C.R., Patterson, T.L., Heaton, R.K., Weaver, C., Anderson, H., Harvey, P.D., Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships?. Schizophr. Res. 89 (2007), 330–338.
31. Moore, D.J., Palmer, B.W., Patterson, T.L., Jeste, D.V., A review of performance-based measures of everyday functioning. J. Psychiatr. Res. 41 (2007), 97–118.
32. Nuechterlein, K.H., Green, M.F., Kern, R.S., Baade, L.E., Barch, D.M., Cohen, J.D., Essock, S., Fenton, W.S., Frese, F.J. III, Gold, J.M., Goldberg, T., Heaton, R.K., Keefe, R.S., Kraemer, H., Mesholam-Gately, R., Seidman, L.J., Stover, E., Weinberger, D.R., Young, A.S., Zalcman, S., Marder, S.R., The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165 (2008), 203–213.
33. Rosenheck, R., Leslie, D., Keefe, R., McEvoy, J., Swartz, M., Perkins, D., Stroup, S., Hsiao, J.K., Lieberman, J., CATIE Study Investigators Group, Barriers to employment for people with schizophrenia. Am. J. Psychiatry 163 (2006), 411–417.
34. Ruse, S.A., Harvey, P.D., Davis, V.G., Atkins, A.S., Fox, K.H., Keefe, R.S., Virtual Reality Functional Capacity Assessment in schizophrenia: preliminary data regarding feasibility and correlations with cognitive and functional capacity performance. Schizophr. Res. Cogn. 1 (2014), e21–e26.
35. Sabbag, S., Twamley, E.M., Vella, L., Heaton, R.K., Patterson, T.L., Harvey, P.D., Assessing everyday functioning in schizophrenia: not all informants seem equally informative. Schizophr. Res. 131 (2011), 250–255.
36. Saykin, A.J., Shtasel, D.L., Gur, R.E., Kester, D.B., Mozley, L.H., Stanfiniak, P., Gur, R.C., Neuropsychological deficits in neuroleptic naive patients with first episode schizophrenia. Arch. Gen. Psychiatry 51 (1994), 124–131.
37. Schneider, L.C., Struening, E.L., SLOF: a behavioral rating scale for assessing the mentally ill. Soc. Work Res. Abstr. 19 (1983), 9–21.
38. Seidman, L.J., Giuliano, A.J., Meyer, E.C., Addington, J., Cadenhead, K.S., Cannon, T.D., McGlashan, T.H., Perkins, D.O., Tsuang, M.T., Walker, E.F., Woods, S.W., Bearden, C.E., Christensen, B.K., Hawkins, K., Heaton, R., Keefe, R.S., Heinssen, R., Cornblatt, B.A., North American Prodrome Longitudinal Study (NAPLS) Group, Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch. Gen. Psychiatry 67 (2010), 578–588.
39. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59 (1998), 22–33.
40. Velligan, D., Mintz, J., Maples, N., Xueying, L., Gajewski, S., Carr, H., Sierra, C., A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. Schizophr. Bull. 39 (2012), 999–1007.
41. Ventura, J., Reise, S.P., Keefe, R.S.E., Hurford, I.M., Wood, R.C., Bilder, R.M., The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition. Schizophr. Bull. 39 (2013), 583–591.